Research
Hormonal
Semaglutide is endorsed for obesity treatment following its FDA approval for type 2 diabetes.
Health practitioners can consider semaglutide as a treatment option for obesity.
StrongSupportsmedium confidence
semaglutide, a ground-breaking GLP-1 agonist, takes the spotlight, tracing its journey from FDA approval for type 2 diabetes to its recent endorsement for obesity.
Why this rating
The claim is based on regulatory approval information.
Source
Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians
Vasiliki-Sofia Grech et al. · Review of Clinical Pharmacology and Pharmacokinetics - International Edition · 2024
DOI 10.61873/rjdb1796
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →